18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies

Chin, B. B.; Wahi, R. L.
June 2003
Gut;Jun2003 Supplement 4, Vol. 52, piv23
Academic Journal
Positron emission tomography with 18F-fluoro-2-deoxyglucose is an imaging technology that is demonstrating increasing utility in the evaluation of gastrointestinal malignancies.


Related Articles

  • Case report: drug interference with MIBG uptake in a patient with metastatic paraganglioma. Zaplatnikov, K.; Menzel, C.; Döbert, N.; Hamscho, N.; Kranert, W. T.; Gotthard, M.; Behr, T. M.; Grünwald, F. // British Journal of Radiology;Jun2004, Vol. 77 Issue 918, p525 

    Metaiodobenzylguanidine (MIBG) labelled with iodine-131 ((131)I) has become a well established therapeutic tool for inoperable metastastic tumours of paraganglioma. There are different pharmacological substances known to interfere with MIBG-uptake which may result in a false negative MIBG scan....

  • The Role for PET Scanning in Breast Cancer Staging. Ershler, William B. // Clinical Oncology Alert;Aug2008, Vol. 24 Issue 8, p62 

    The article discusses research on the role of positron emission tomography (PET) scanning in determining the stage of Breast cancer for patients in whom recurrent disease is suspected. It references a study by S. Mahner et al, published in "Annals of Oncology." PET, using 2-[fluorine-18]...

  • Multimodality imaging in Europe: a survey by the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR). Cuocolo, Alberto; Breatnach, Éamann // European Journal of Nuclear Medicine & Molecular Imaging;Jan2010, Vol. 37 Issue 1, p163 

    Multimodality imaging represents an area of rapid growth with important professional implication for both nuclear medicine physicians and radiologists throughout Europe. As a preliminary step for future action aimed at improving the quality and accessibility of PET/SPECT/CT multimodality imaging...

  • FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Boellaard, Ronald; O'Doherty, Mike; Weber, Wolfgang; Mottaghy, Felix; Lonsdale, Markus; Stroobants, Sigrid; Oyen, Wim; Kotzerke, Joerg; Hoekstra, Otto; Pruim, Jan; Marsden, Paul; Tatsch, Klaus; Hoekstra, Corneline; Visser, Eric; Arends, Bertjan; Verzijlbergen, Fred; Zijlstra, Josee; Comans, Emile; Lammertsma, Adriaan; Paans, Anne // European Journal of Nuclear Medicine & Molecular Imaging;Jan2010, Vol. 37 Issue 1, p181 

    The aim of this guideline is to provide a minimum standard for the acquisition and interpretation of PET and PET/CT scans with [18F]-fluorodeoxyglucose (FDG). This guideline will therefore address general information about [18F]-fluorodeoxyglucose (FDG) positron emission tomography-computed...

  • Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT. Prasad, Vikas; Ambrosini, Valentina; Hommann, Merten; Hoersch, Dieter; Fanti, Stefano; Baum, Richard // European Journal of Nuclear Medicine & Molecular Imaging;Jan2010, Vol. 37 Issue 1, p67 

    This bi-centric study aimed to determine the role of receptor PET/CT using 68Ga-DOTA-NOC in the detection of undiagnosed primary sites of neuroendocrine tumours (NETs) and to understand the molecular behaviour of the primarily undiagnosed tumours. Overall 59 patients (33 men and 26 women, age:...

  • Validation of cardiac 123I-MIBG scintigraphy in patients with Parkinson’s disease who were diagnosed with dopamine PET. Ishibashi, Kenji; Saito, Yuko; Murayama, Shigeo; Kanemaru, Kazutomi; Oda, Keiichi; Ishiwata, Kiichi; Mizusawa, Hidehiro; Ishii, Kenji // European Journal of Nuclear Medicine & Molecular Imaging;Jan2010, Vol. 37 Issue 1, p3 

    The aim of this study was to evaluate the diagnostic potential of cardiac 123I-labelled metaiodobenzylguanidine (123I-MIBG) scintigraphy in idiopathic Parkinson’s disease (PD). The diagnosis was confirmed by positron emission tomography (PET) imaging with 11C-labelled...

  • Iatrogenic FDG foci in the lungs: a pitfall of PET image interpretation. Hany, Thomas F.; Heuberger, Juerg; von Schulthess, Gustav K. // European Radiology;Sep2003, Vol. 13 Issue 9, p2122 

    2-[F-18]-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) has become an important staging modality for many tumors, including bronchial carcinoma; however it is important to know that there are several pitfalls in PET image interpretation. In this report we demonstrate three...

  • Comparison of pharmacokinetic MRI and [18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience. Brix, Gunnar; Henze, Marcus; Knopp, Michael V.; Lucht, Robert; Doll, Josef; Junkermann, Hans; Hawighorst, Hans; Haberkorn, Uwe // European Radiology;Oct2001, Vol. 11 Issue 10, p2058 

    It was the aim of this methodology-oriented clinical pilot study to compare the potential of dynamic MRI and 2-[18F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) for the detection and characterization of breast cancer. Fourteen women with suspicious breast lesions were...

  • ACC notebook.  // Medical Device Daily;4/1/2009, Vol. 13 Issue 61, p3 

    The article reports on the presentation of Phase I data on the safety and tolerability of BMS747158, a fluorine 18-labeled Positron Emission Tomography (PET) tracer for myocardial perfusion imaging in subjects under rest and stress conditions, by Lantheus Medical Imaging at the American College...


Read the Article


Sign out of this library

Other Topics